Date of Award
2020
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Jodi Freeman
Abstract
Patients with moderate-severe asthma are dependent on beta-agonists and inhaled corticosteroids for maintenance, and oral corticosteroids for acute exacerbations. New approaches to the treatment of moderate-severe asthma have emerged, including agents that target interleukin-4, a key player in the inflammatory pathway of asthma. These medicines include Dupilumab and Pitrakinra. This study found that dupilumab is effective in controlling asthma symptoms and was recently FDA approved for treatment of moderate-severe asthma in those 12 years old and older, but studies of pitrakinra have ceased.
Recommended Citation
Ortega, Jessica, "Efficacy of Interleukin-4 Receptor Monocloncal Antibody (Dupilumab) and Interleukin-4 Antagonist (Pitrakinra) in the Treatment of Moderate-Severe Asthma" (2020). Capstone Showcase. 42.
https://scholarworks.arcadia.edu/showcase/2020/pa/42
Efficacy of Interleukin-4 Receptor Monocloncal Antibody (Dupilumab) and Interleukin-4 Antagonist (Pitrakinra) in the Treatment of Moderate-Severe Asthma
Patients with moderate-severe asthma are dependent on beta-agonists and inhaled corticosteroids for maintenance, and oral corticosteroids for acute exacerbations. New approaches to the treatment of moderate-severe asthma have emerged, including agents that target interleukin-4, a key player in the inflammatory pathway of asthma. These medicines include Dupilumab and Pitrakinra. This study found that dupilumab is effective in controlling asthma symptoms and was recently FDA approved for treatment of moderate-severe asthma in those 12 years old and older, but studies of pitrakinra have ceased.